LSL Web-Exclusive Content

  1. Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch

    Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.

  2. Commissioner Gottlieb, CAR T-Cells, & The Future Of Rare Disease Therapies

    FDA Commissioner Scott Gottlieb has taken the wheel at an exciting time, when insights from genomics are starting to come to fruition and promising new therapies based on new technologies are being developed. This article explores some of the policy changes happening now in the regulatory rare disease space — and shifts we expect to see in the future — as the FDA’s leadership team implements these changes at the agency.

  3. How to Get the Maximum Value from Your Market Research Data

    Generally, the market intelligence that’s behind a successful life science market strategy isn’t public, but if you could take a peek, you’d likely find these four best practices.

  4. Leaders: When You Talk, Is Anybody Listening? How to Become an Influential Communicator

    Amid today’s rapid-fire business climate and the ever-changing healthcare landscape, it’s not unusual for leaders to move quickly. Fast is fine, but are you going too fast, too often? Are you sure your leadership style isn’t leaving people in the dust or pushing them away?

  5. When Regulatory Goes Wrong

    In spite of my preference for “happily ever-after” as detailed in a previous article, sometimes things do not go well for medical device companies as it pertains to regulatory affairs.

  6. How Interested Is The FDA In Real-World Evidence?

    When the Clinical Leader team attended the 2017 DIA Annual Meeting in June, the topic we heard discussed more than any other was real-world evidence (RWE) — that is, information about a drug that is collected outside of clinical trials. RWE is not a new concept, but there are good reasons for all the current attention being paid to it in the pharma industry.

  7. Why Pharma Needs A New Approach To Patient Engagement In Drug Development

    Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny, all while trying to satisfy investors. As drug prices seem to be continually rising, many health plans are shifting more of the cost-sharing burden to patients.  As a result, the patient is becoming more of a “consumer” in the traditional sense.

  8. Pfenex’s New CEO Sizes Up Biosimilar Industry’s Future

    Newly-appointed Pfenex CEO, Eef Schimmelpennink, faces the challenge of determining how to adapt Pfenex to a constantly changing future. Though it's still very early in his tenure, Schimmelpennink highlights some areas he will keep in mind as he steers Pfenex's future biosimilars onto the market.  

  9. Can New York City Lead In Life Sciences?

    New York City has long aspired to become a life sciences hub, but while the city seems to have all the elements necessary to foster such industry growth, it has continually fallen short of this goal. 

  10. Can Biosimilars Increase The Profitability Of Generics Manufacturers?

    Generic drug prices are falling. For confirmation, look no further than the recent earnings reports from generic manufacturers and pharmaceutical wholesalers whose profits from distributing generic pharmaceuticals are also declining.